Abstract
The Notch signaling pathway is a highly conserved pathway in most multicellular organisms. It is of critical importance for cell proliferation, differentiation, and homeostasis. Aberrant Notch signaling can give rise to a number of pathologies including cancer. The Notch signaling pathway consists of a well-orchestrated series of biochemical events that provide multiple avenues for rational drug design. Design of targeted therapies focusing on Notch signaling is rapidly advancing. This review will aim to discuss the established and recent approaches to targeting the Notch pathway.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yamamoto S, Schulze KL, Bellen HJ. Introduction to notch signaling. Methods Mol Biol. 2014;1187:1–14.
Braune EB, Lendahl U. Notch – a goldilocks signaling pathway in disease and cancer therapy. Discov Med. 2016;21(115):189–96.
Espinoza I, et al. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 2013;6:1249–59.
Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene. 2000;19(37):4191–8.
Rizzo P, et al. Rational targeting of notch signaling in cancer. Oncogene. 2008;27(38):5124–31.
Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013;139(2):95–110.
Fender AW, et al. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J Cell Biochem. 2015;116(11):2517–27.
Panneerselvam J, Munshi A, Ramesh R. Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities. J Mol Signal. 2013;8(1):15.
Pannuti A, et al. Targeting notch to target cancer stem cells. Clin Cancer Res. 2010;16(12):3141–52.
Even C, et al. Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC). J Clin Oncol. 2017;35(suppl; abstr 6024).
Chiorean EG, et al. A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin Cancer Res. 2012;21(12):2695–703.
Kavalerchik E, et al. An open-label study of rovalpituzumab tesirine in patients with DLL3-expressing advanced solid tumors. J Clin Oncol. 2017;35(suppl; abstr TPS2597).
Caffo M, et al. Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci. 2013;14(1):2135–74.
Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141(2):140–9.
Nowell CS, Radtke F. Notch as a tumor suppressor. Nat Rev Cancer. 2017;17:145–59.
Conflict of Interest
The authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zlobin, A., Bloodworth, J.C., Baker, A.T., Osipo, C. (2019). Notch Signaling Pathway in Carcinogenesis. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)